Sandimmun Concentrate for Infusion 50mg/1ml Ampoule

Manufacturer

NOVARTIS PHARMA STEIN AG

 

Contents

Ciclosporin

 

Indication

Transplantation: Solid organ transplantation (kidney, liver, heart, combined heart-lung, lung, pancreas); bone marrow transplantation. Non-transplantation: Endogenous uveitis; nephrotic syndrome; severe active rheumatoid arthritis; severe psoriasis; severe atopic dermatitis.

 

Instruction

Administer via IV Infusion over approximately 2 to 6 hours.

 

Drug interaction

Not recommended w/ live attenuated vaccines. Caution is recommended in administration w/ K-sparing & -containing drugs, lercanidipine. Increased or decreased ciclosporin levels by barbiturates, carbamazepine, oxcarbazepine, phenytoin, rifampicin, nafcillin, sulfadimidine IV, octreotide, probucol, orlistat, Hypericum perforatum (St. John's wort), ticlopidine, sulfinpyrazone, terbinafine, bosentan, macrolides (eg, erythromycin, azithromycin, clarithromycin), ketoconazole, fluconazole, itraconazole, voriconazole, diltiazem, nicardipine, verapamil, metoclopramide, OCs, danazol, methylprednisolone (high dose), allopurinol, amiodarone, cholic acid & derivatives, protease inhibitors, imatinib, nefazodone. Potential increased nephrotoxicity w/ aminogylcosides, amphotericin B, ciprofloxacin, vancomycin, melphalan, trimethoprim, (w/ sulfamethoxazole), NSAIDs (including diclofenac), H2-receptor antagonists, tacrolimus, methotrexate, fibric acid derivatives (eg, bezafibrate, fenofibrate). Increased rate of gingival hyperplasia w/ nifedipine. Increased plasma levels of HMG-CoA reductase inhibitors (statins), colchicine, digoxin, etoposide, everolimus, sirolimus, repaglinide, aliskerin, dabigatran, bosentan, ambrisentan & anthracyclines (eg, doxorubicine).